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Introduction: Intestinal dysmotility following human necrotizing enterocolitis suggests that the enteric nervous
system is injured during the disease. We examined human intestinal specimens to characterize the enteric nervous
system injury that occurs in necrotizing enterocolitis, and then used an animal model of experimental necrotizing
enterocolitis to determine whether transplantation of neural stem cells can protect the enteric nervous system from
injury.
Methods: Human intestinal specimens resected from patients with necrotizing enterocolitis (n = 18), from control
patients with bowel atresia (n = 8), and from necrotizing enterocolitis and control patients undergoing stoma
closure several months later (n = 14 and n = 6 respectively) were subjected to histologic examination,
immunohistochemistry, and real-time reverse-transcription polymerase chain reaction to examine the myenteric
plexus structure and neurotransmitter expression. In addition, experimental necrotizing enterocolitis was induced
in newborn rat pups and neurotransplantation was performed by administration of fluorescently labeled neural
stem cells, with subsequent visualization of transplanted cells and determination of intestinal integrity and
intestinal motility.
Results: There was significant enteric nervous system damage with increased enteric nervous system apoptosis,
and decreased neuronal nitric oxide synthase expression in myenteric ganglia from human intestine resected for
necrotizing enterocolitis compared with control intestine. Structural and functional abnormalities persisted months
later at the time of stoma closure. Similar abnormalities were identified in rat pups exposed to experimental
necrotizing enterocolitis. Pups receiving neural stem cell transplantation had improved enteric nervous system and
intestinal integrity, differentiation of transplanted neural stem cells into functional neurons, significantly improved
intestinal transit, and significantly decreased mortality compared with control pups.
Conclusions: Significant injury to the enteric nervous system occurs in both human and experimental necrotizing
enterocolitis. Neural stem cell transplantation may represent a novel future therapy for patients with necrotizing
enterocolitis.* Correspondence: gail.besner@nationwidechildrens.org
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Necrotizing enterocolitis (NEC) is the most common
gastrointestinal emergency in neonates and the leading
cause of death in premature babies [1]. Current overall
mortality rates are ~30%, with higher rates for very low
birth weight babies. This high morbidity and mortality
represent a significant medical problem and a costly bur-
den to society.
Although the pathogenesis of NEC is not completely
understood, prematurity is considered the most import-
ant risk factor for the development of the disease. In
addition, exclusive formula feeding is associated with an
increased incidence of NEC, while promotion of breast
milk feeding may decrease the incidence of NEC [2-4].
The enteric nervous system (ENS), located in the wall of
the intestine, is the largest and most complex division of
the peripheral nervous system. The newborn ENS is not
fully developed at birth and undergoes neuroplasticity
during early postnatal stages [5]. The content of neuro-
trophic factors and cytokines in human breast milk con-
tribute to the postnatal development of the ENS [6]. An
immature ENS has been observed in premature infants,
represented as decreased organized intestinal motility. It
is thought that this intrinsic ENS immaturity may con-
tribute to the development of NEC [7]. Intestinal motil-
ity is mainly regulated by neurotransmitters produced
by myenteric neurons. Neuronal nitric oxide synthase
(nNOS)-producing neurons and choline acetyl transfer-
ase (chAT)-producing neurons are involved in the regu-
lation of intestinal motility, and nNOS/chAT misbalance
has been reported in certain intestinal motility disorders
[8]. Loss of enteric neurons in the submucosa has been
demonstrated in patients with NEC, and some reports
have shown NEC-induced myenteric plexus alterations
[9,10]. In addition, post-NEC complications such as in-
testinal dysmotility, stricture, and recurrent abdominal
distention have been widely reported [11,12]. The intes-
tinal dysfunction that is present after successful medical
or surgical management of NEC suggests that the com-
promised ENS is not fully recovered from the acute in-
testinal insult.
Similar to the central nervous system, neurons in the
ENS have restricted potential for regeneration after injury.
Limited neurogenesis may lead to a failure to reverse the
neuronal cell loss that occurs during NEC, leading to
compromised intestinal function long after recovery from
the acute disease. Transplantation of intestinal enteric
neurons to restore the neuronal cell loss associated with
NEC may represent a future therapeutic option.
In the current study we have documented ENS abnor-
malities in patients with NEC. Furthermore, we have ad-
ministered neural stem cells (NSCs) to rat pups with
experimental NEC, documented engraftment of the
transplanted NSCs in injured intestine, and confirmedimproved ENS integrity and intestinal motility post
transplantation.
Materials and methods
Human intestinal tissue collection
Approval for the use of human intestinal tissues was
obtained from the Institutional Review Board of Nation-
wide Children’s Hospital, Columbus, OH, USA (Protocol #
06-00267). This protocol met the guidelines for waiver of
informed consent. Intestinal tissue specimens were ob-
tained from 18 neonates with acute NEC (gestational
age range 24 to 37 weeks, mean gestational age 32.1 ±
2.7 weeks, age range 4 to 21 days; mean age 10.7 ±
5.5 days) and eight control patients (gestational age range
28 to 36 weeks, mean gestational age 35.9 ± 1.4 weeks,
age range 1 to 6 days; mean age 1.7 ± 1.4 days) with small
bowel atresia. All patients chosen for examination
underwent initial bowel resection with ostomy creation
followed by subsequent stoma closure 2 to 3 months
later. Intestinal samples were obtained from the antime-
senteric border of the intestines for consistency, given
that the ENS distribution in the intestine is variable
[13]. Intestinal samples were subjected to RNA ex-
traction, and to hematoxylin and eosin staining and
immunohistochemistry.
Neural stem cell culture
Enteric NSCs were generated using a modification of a
previously described method [14]. Time mated c57BL/6-
Tg (pan-EGFP) mice (Jackson Laboratory, Bar Harbor,
MA, USA) were sacrificed and intestines from 12.5-day
post‐coitum embryos were dissected into Dulbecco’s
modified Eagle’s medium/Ham’s nutrient mixture F12
(DMEM/F12; Invitrogen, Carlsbad, CA, USA). Intestines
were dissociated in 50 μg/ml dispase and 50 μg/ml colla-
genase (Worthington Biochemical, Freehold, NJ, USA)
for 60 minutes at 37°C. Intestines were triturated and fil-
tered through 40 μm cell strainers to obtain single cell
suspensions. Cells were cultured in 35 mm Petri dishes
in NSC culture medium consisting of DMEM/F12 con-
taining 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen), supplemented with 2 mmol/l L-glutamine
(Invitrogen), 7.5% (v/v) chick embryo extract (Gemini
Bio-products, West Sacramento, CA, USA), 1% (v/v) N2
medium supplement (Sigma‐Aldrich, St Louis, MO,
USA), 20 ng/ml mouse basic fibroblast growth factor,
and 20 ng/ml mouse epidermal growth factor (Sigma‐
Aldrich). NSCs grew as free-floating cellular aggregates
known as neurosphere-like bodies.
Animal model of experimental necrotizing enterocolitis
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of the Research
Institute at Nationwide Children’s Hospital (Protocol #
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described previously [15,16]. Rat pups were delivered on
day 21 of gestation by Cesarean section from timed
pregnant rats (Harlan Sprague–Dawley, Indianapolis, IN,
USA). Newborn rat pups in the experimental NEC group
were maintained in an incubator at 37°C and gavage fed
with hypertonic formula containing 15 g Similac 60/40
(Ross Pediatrics, Columbus, OH, USA) in 75 ml Esbilac
(Pet-Ag, New Hampshire, IL, USA), a diet that provided
836.8 kJ/kg daily. Pups were exposed to hypoxia with
100% nitrogen for 1 minute followed by hypothermia
at 4°C for 10 minutes twice daily beginning 60 mi-
nutes after birth for 3 days, with intragastric feeding
of lipopolysaccharide (2 mg/kg; Sigma‐Aldrich) 8 hours
after birth.
Animal model of recovery from necrotizing enterocolitis
Animals that survived the exposure to experimental
NEC described above were recovered by discontinuing
exposure to hypoxia/hypothermia on day 3 of life, and
then switching pups to normal formula feeding for an
additional 4 days to mimic recovery from NEC. On
day 3, an intraperitoneal (i.p.) injection of NSCs was
performed as described by Martucciello and colleagues
[17]. Experimental pups received a single i.p. injection of
NSC (50,000 cells in 50 μl DMEM/F12) into the right
lower quadrant, while control animals received the same
amount of medium carrier intraperitoneally. Normal
control pups, designated the breast milk group, were
breast fed using surrogate mothers and were not ex-
posed to stress.
Immunohistochemistry and confocal microscopy
Tissue sections (4 μm thickness) from 4% paraformaldehyde-
fixed paraffin-embedded human or rat intestine were sub-
jected to immunohistochemistry with specific primary
antibodies: mouse anti-human neuronal protein HuC/D
(10 μg/ml), rabbit anti-nNOS (2 μg/ml), chicken anti-
green fluorescence protein (GFP; 1 μg/ml) (all from
Invitrogen); chicken anti-glial fibrillary acid protein
(GFAP; 1:1,000), rabbit anti-protein gene product 9.5
(1:500), rabbit anti-peripherin (1:100) (all from Millipore,
Billerica, MA, USA); and rabbit anti-cleaved caspase 3
(1:500; Cell Signaling, Danvers, MA, USA). After being
washed in phosphate-buffered saline, sections were incu-
bated with fluorophore-conjugated goat anti-mouse IgG
(Alexa 647; Molecular Probes, Eugene, OR, USA), anti-
rabbit IgG (Alexa 488; Molecular Probes) or anti-chicken
Igγ (Cy3; Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) at room temperature. Sections were
counterstained with 4′,6-diamidino-2-phenylindole. For
immunocytochemistry of NSCs, free-floating neurosphere-
like bodies were seeded in poly-D-lysine/laminin-coated
eight-well chamber slides (BD Bioscience, Bedford,MA, USA) and cultured for an additional 12 hours. To
detect nestin expression, neurospheres were incubated
with mouse monoclonal antibody Rat-401 (1:100; De-
velopmental Studies Hybridoma Bank of the University
of Iowa, Iowa City, IA, USA) overnight at 4°C and then
recognized by fluorophore-conjugated goat anti-mouse
IgG (Cy3; Jackson ImmunoResearch Laboratories). For
NSC differentiation studies, neurospheres were grown
in differentiation medium (DMEM/F12 + 10% fetal bo-
vine serum) for 4 days. Differentiated cells were recog-
nized by monoclonal rabbit anti-neuronal class III
β-tubulin (Tuj1, 1 μg/ml; Covence, Princeton, NJ, USA)
and polyclonal chicken anti-GFAP (1:1,000) respect-
ively. Fluorescence images were captured by confocal
microscopy (LSM 710; Carl Zeiss, Thornwood, NY,
USA). Images were analyzed using image analysis soft-
ware (Image Pro Plus; Media Cybernetics, Silver Springs,
MD, USA).
Morphology of myenteric plexuses
Cross-sections from human intestinal specimens were used
to identify enteric ganglia in myenteric plexuses located be-
tween the intestinal longitudinal and circular muscular
layers. Intestinal tissue strips were dissected from the anti-
mesenteric border of the intestines, and 10 serial sections
with a thickness of 4 μm each were examined in order to
reduce the possibility of biased observations. Human my-
enteric plexuses were identified by groups of HuC/D im-
munoreactive neuronal somata surrounded by glial cells.
Total myenteric ganglion numbers in each section were re-
corded. Neurons were recognized by HuC/D-immunoreac-
tivity, which was displayed as an artificial gray color, and
neurons were quantified as the mean neuronal number
per ganglion. nNOS-expressing functional neurons immu-
noreactive for nNOS were also counted, and the ratio of
nNOS-expressing neurons to total HuC/D immunoreactive
neurons per ganglia was calculated. The appearance of glial
cells in the myenteric plexus, as displayed by GFAP immu-
noreactivity, showed very small nuclei with elongated and
interconnected processes in the myenteric plexus, making
it very difficult to count the glial cells directly. Since my-
enteric ganglia mainly consist of neurons and supportive
glial cells, total glial cell numbers in each ganglion were ex-
trapolated by subtracting the number of neurons from the
total cell numbers as recognized with 4′,6-diamidino-2-
phenylindole staining. Lastly, the myenteric neuronal cell
area (HuC/D+-stained area) and the myenteric ganglion
area were measured in blinded samples using Image Pro
Plus software (Media Cybernetics), and the ratio of the
areas was calculated [18].
Real-time reverse-transcription polymerase chain reaction
Longitudinal muscle–myenteric plexus (LMMP) strips
consisting of the myenteric plexus and the innervated
Zhou et al. Stem Cell Research & Therapy 2013, 4:157 Page 4 of 13
http://stemcellres.com/content/4/6/157longitudinal muscles were dissected from fresh human
intestines. Total RNA was reverse-transcribed with ran-
dom hexamers using a first-strand cDNA synthesis
kit (Invitrogen-Gibco). Real-time reverse-transcription
polymerase chain reaction (RT-PCR) was carried out
using a SYBR Green RT-PCR kit (Applied Biosystems,
Branchburge, NJ, USA) and an ABI Prism 770 Sequence
Detection System (Applied Biosystems). Human nNOS
and chAT were amplified using the following primers:
nNOS sense, 5′-GGCCCATATTAATCCCTCGT-3′ and
nNOS anti-sense, 5′-ACATGAGGGCTCTGCTCACT-3′;
chAT sense, 5′-CCACTCCATTCCCACTGACT-3′ and
chAT anti-sense, 5′-GAGACGGCGGAAATTAATGA-3′.
Amplification of the housekeeper gene (glyceraldehyde
3-phosphate dehydrogenase) cDNA was used as an in-
ternal control for quantification. Quantification was per-
formed using Relative Quantification Software, version
1.01 (Applied Biosystems).
Western blotting
LMMP strips of intestines from rat pups were isolated
4 days after NSC transplantation. Tissue lysates were
subjected to SDS-PAGE and proteins were trans-
ferred to nitrocellulose membranes and subjected to
immunoblot analysis. Peripherin, GFAP, and nNOS
were detected using primary antibodies followed by
horseradish peroxidase-conjugated secondary antibo-
dies. Blots were developed with the ECL Plus system
(Amersham Biosciences, Piscataway, NJ, USA) using
Hyperfilm (Amersham Biosciences) for exposure. The
intensity of immunoreactive bands on western blots
was quantified using the Scion Image Program (Scion
Corporation, Frederick, MD, USA) and expressed as
the mean ± standard error of the mean.
Intestinal motility assay
Four days after NSC transplantation, rat pups were made
nil per os for 4 hours followed by administration of
0.2 ml methylene blue-labeled 10% dextrose solution
(Sigma-Aldrich) delivered by duodenal gavage. Animals
were euthanized 5 minutes after introduction of the dye.
Intestinal transit was measured from the pylorus to the
most distal point of migration of the blue dye. The total
length of the small intestine was measured and the ratio
of dye migration distance/total intestinal length was cal-
culated and transit times were expressed as a percentage
of the total intestinal length [19].
Statistical analyses
All data are presented as the mean ± standard error of
the mean. Statistical analyses were performed using the
Student t test or one-way analysis of variance (SigmaPlot
11.0; Systat Software, Inc. San Jose, CA, USA). Absolute
P values are shown, with P <0.05.Results
Enteric nervous system is injured in human
necrotizing enterocolitis
We compared human intestinal specimens from patients
undergoing initial bowel resection for small bowel atre-
sia or for NEC, as well as stoma closure specimens
several months later. A review of hospital pathology re-
ports revealed no mention of pathological changes in the
ENS of these patients. We began by assessing histo-
logical changes in hematoxylin-and-eosin-stained tissue
sections. Compared with control intestine, acute NEC
was associated with severe epithelial damage (Figure 1A).
Ganglion cells were present in the myenteric plexus
of NEC patients (Figure 1B). We then performed immu-
nohistochemistry using antibodies against HuC/D (a
general neuronal marker to identify all neurons), GFAP
(to identify glial cells), and nNOS (to identify nNOS-
producing neurons). Whereas myenteric ganglia from
bowel atresia specimens contained densely populated
HuC/D-labeled neurons packed together in a character-
istically tight fashion, ganglia from acute NEC specimens
contained loosely packed HuC/D-labeled neurons with
varying degrees of interneuronal spaces and considerable
variation in cell body appearance (Figure 1C). Signifi-
cantly decreased immunostaining for HuC/D, GFAP
and nNOS was present in the myenteric ganglia of
acute NEC specimens compared with bowel atresia
specimens (Figure 1C). GFAP-positive glial cells and
nNOS-expressing cells remained low in the ganglia of
stoma specimens from patients who underwent initial
bowel resection for NEC compared with stoma speci-
mens from patients who underwent initial surgery for
bowel atresia (Figure 1D).
Quantification of the numbers of cells per ganglion
confirmed that the number of HuC/D-positive total neu-
rons per ganglia was significantly reduced in specimens
from patients with acute NEC compared with bowel
atresia (5.19 ± 1.20 vs. 7.62 ± 0.61, P <0.05) (Figure 2A).
The number of glial cells per ganglia was also signifi-
cantly reduced in specimens from patients with acute
NEC compared with bowel atresia (8.41 ± 1.12 vs. 15.8 ±
0.82, P <0.05), and these glial cell numbers remained
low months later at the time of stoma closure (11.2 ±
0.73 vs. 18.4 ± 0.67, P <0.05) (Figure 2B). Although both
neuronal and glial cell loss was found in the myenteric
plexuses of NEC patients, there was no reduction in the
overall size of the myenteric plexuses in NEC patients,
either during acute NEC or at the time of stoma closure
(during acute disease: NEC 27,197 ± 7,125 μm2 vs. bo-
wel atresia 29,019 ± 12,310 μm2, P >0.05; at stoma clo-
sure: NEC 29,227 ± 9,145 μm2 vs. bowel atresia 30,115 ±
7,125 μm2, P >0.05). However, the ratio of the cytoplas-
mic area of HuC/D immunoreactive neurons to my-
enteric ganglion area or neural packing density was
Figure 1 Structural and functional abnormities exist in myenteric plexus ganglia of necrotizing enterocolitis patients. (A) Representative
hematoxylin-and-eosin-stained sections from human small intestine resected for small bowel atresia (BA) in a newborn 33-week-gestation infant
compared with an 11-day-old 31-week-gestation baby with necrotizing enterocolitis (NEC). The control intestine shows a normal appearance of
the intestine whereas epithelial sloughing was present in the intestine resected for NEC. (B) High-magnification images of myenteric ganglia
(arrows) from a BA patient and a NEC patient (arrows). Ganglion cells are present in the myenteric plexus of intestinal sections in both images.
(C), (D) Myenteric ganglia were subjected to immunohistochemistry using antibodies to HuC/D (gray staining of total neurons), glial fibrillary acid
protein (GFAP; red staining of glial cells), and neuronal nitric oxide synthase (nNOS; green staining of functional neurons producing nNOS).
4′,6-Diamidino-2-phenylindole was used to counterstain nuclei. (C) Bowel resected for acute disease. (D) Bowel resected during stoma closure
2 to 3 months later. Scale bar: (A) 10 μm; (B), (C), (D) 50 μm.
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patients with bowel atresia (Figure 2C). In addition, the
ratio of nNOS-expressing neurons to total HuC/D im-
munoreactive neurons was significantly decreased in the
myenteric ganglia from NEC patients compared with
bowel atresia patients both during the acute episode
(0.26 ± 0.04 vs. 0.34 ± 0.03) and later during stoma clos-
ure (0.29 ± 0.03 vs. 0.36 ± 0.02) (Figure 2D).
Since nNOS and chAT are important regulators of
intestinal motility, we next investigated nNOS andchAT mRNA expression in our intestinal samples. Since
nNOS-expressing neurons are abundant in the my-
enteric plexus compared with the submucosal plexus
[20], we intentionally removed the circular muscular
layer and its tightly attached submucosal plexus in order
to prepare LMMP strips for RT-PCR analysis of the
myenteric plexus alone in these experiments. Real-time
RT-PCR confirmed that acute NEC was associated
with significantly decreased expression of both nNOS
and chAT (Figure 2E, F). Whereas nNOS expression
Figure 2 Neuronal and glial cell loss occurs in myenteric plexus ganglia of necrotizing enterocolitis patients. Intestinal specimens were
examined from patients with acute necrotizing enterocolitis (NEC; n = 18), from age-matched patients with small bowel atresia (BA; n = 8), from
NEC patients undergoing stoma closure (n = 14), and from BA patients undergoing stoma closure (n = 6). (A) Neuronal cell numbers in the
myenteric ganglia were counted and neurons per ganglion presented as mean ± standard error of the mean. (B) The number of glial cells
per ganglion was extrapolated by subtracting the number of HuC/D-positive neurons from the total numbers of with 4′,6-diamidino-2-phenylindole-
labeled nuclei. (C) The ratio of the cytoplasmic area of HuC/D immunoreactive (IR) neurons to myenteric ganglionic area was calculated. (D) Neuronal
nitric oxide synthase (nNOS) and HuC/D double-labeled cells in myenteric plexuses were counted and the ratio of nNOS-expressing neurons to total
HuC/D stained neurons was calculated. (E) mRNA expression of nNOS as determined by real-time reverse-transcription polymerase chain reaction
(RT-PCR). (F) mRNA expression of choline acetyl transferase (chAT) as determined by real-time RT-PCR. *P <0.05; +P <0.01.
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stoma closure. The disturbed expression of nNOS and
chAT in the intestine during and after NEC suggests
that ENS functions are disrupted even during the
recovery phase.
To determine whether the neuronal cell loss found in
NEC was due to apoptosis, we assessed neuronal apop-
tosis by cleaved caspase-3 immunohistochemistry. Associ-
ated with the decreased numbers of total neurons and
glial cells, we found increased numbers of caspase 3-
positive cells per ganglia in the myenteric plexus andsubmucosal plexus of intestine resected for NEC com-
pared with control intestine (Figure 3A, B). Quantification
revealed that the numbers of cleaved caspase-3-positive
cells per ganglia were significantly increased in the
myenteric plexus of specimens from acute NEC patients
compared with bowel atresia patients (17.2 ± 3.1% vs.
1.5 ± 0.87%, P <0.05) (Figure 3C). Significantly increased
neuronal apoptosis was also present in the submucosal
plexus of specimens from acute NEC patients compared
with bowel atresia patients (58.7 ± 7.6 vs. 4.9 ± 2.7%,
P <0.05) (Figure 3D).
Figure 3 Increased apoptosis is present in the myenteric plexus ganglia of necrotizing enterocolitis patients. (A), (B) Myenteric ganglia
and submucosal ganglia respectively were subjected to immunohistochemistry using antibodies to HuC/D (neurons), glial fibrillary acid protein
(GFAP; glial cells), and cleaved caspase 3 (apoptotic cells). Scale bar: 50 μm. (C), (D) Cleaved caspase-3-positive neurons were counted and
expressed as the percentage of total HuC/D stained neurons in ganglia from the myenteric plexus (M. plexus) and the submucosal plexus
(S. plexus), respectively. Values represent mean ± standard error of the mean, with data generated from the intestines from 11 patients with
acute necrotizing enterocolitis (NEC) and six patients with small bowel atresia (BA). *P < 0.05 versus control, +P < 0.01 versus control.
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Previous studies have demonstrated that NSCs isolated
from embryonic guts were able to proliferate in response
to epidermal growth factor and basic fibroblast growth
factor in serum-free culture conditions to generate
clonal aggregates of undifferentiated neural precursor
cells [21,22]. In agreement with the studies from other
laboratories [23], separate clonogenic assays of NSCs
from fetal or postnatal intestinal tissue were performed
in our laboratory, and demonstrated a higher prolifera-
tion rate of fetal NSC colonies than their postnatal
counterparts. Based on these findings, fetal intestine
was harvested from pan-EGFP mice at embryonic day
12.5 and dissociated with enzymatic digestion. From
days 1 to 21, colonies grew in size and formed neuro-
spheres (Figure 4A). Nestin immunostaining confirmed
the presence of significant numbers of neural precursor
cells in the neurospheres and EGFP-labeled cells were
easily visualized by the green florescence (Figure 4B).
After withdrawal of growth factors, NSCs were inducedto differentiate into neurons and glial cells that were rec-
ognized by Tuj1 and GFAP immunostaining respectively,
confirming that enteric NSCs are the lineage precursors
to neuronal and glial cells (Figure 4C).
Enteric nervous system is injured in experimental
necrotizing enterocolitis
Similar to human NEC, intestinal sections from pups ex-
posed to experimental NEC demonstrated epithelial cell
sloughing and villous necrosis (Figure 5A). Again similar
to our human NEC findings, pups subjected to experi-
mental NEC had decreased total neuronal cells, glial
cells, and nNOS-expressing cells in the injured intestines
compared with breast-fed pups (Figure 5B).
Neural stem cell transplantation preserves enteric
nervous system integrity in experimental
necrotizing enterocolitis
We developed a novel model for recovery from NEC-
induced intestinal dysmotility in which rat pups are
Figure 4 Morphologic and immunocytochemical analysis of
enteric neurospheres. (A) Appearance of neurospheres generated
from neural stem cells (NSCs) isolated from embryonic day 12.5
intestine of pan-EGFP mice grown for 1, 7 and 21 days in culture. (B)
Appearance of neurospheres on day 21 of culture showing green
fluorescent protein (GFP) labeling of all cells, immunostaining for
nestin (specific marker of neural stem cells), and the merged images.
(C) Neurospheres were induced to differentiate into neurons and
glial cells after withdrawal of growth factors, and were grown in
poly-D-lysin/laminin-coated slide chambers for 4 days. Differentiated
neurons and glial cells were recognized by Tuj1 and glial fibrillary
acid protein (GFAP) staining respectively. D1, day 1; D7, day 7; D21,
day 21. Scale bars: 50 μm.
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for 3 days, and are then maintained on normal feeds with-
out stress for an additional 4 days (Figure 6A). As opposed
to the standard NEC model, which is useful for assessing
intestinal pathology during acute NEC, this modified NECFigure 5 Injury to the enteric nervous system occurs in experimental
stained sections from a breast-fed rat pup with normal intestine, and a rat
with epithelial sloughing and villous necrosis. (B) HuC/D, glial fibrillary acid
tochemistry, with merged images shown.model demonstrates changes in the intestines that are
present during recovery from NEC. We delivered GFP-
labeled enteric NSC via i.p. injection after the 3-day period
of stress. To determine whether transplanted enteric
NSCs home to the ENS and differentiate into neurons, we
performed double immunofluorescence staining for GFP
and for the pan-neuronal marker protein gene product
9.5. We found that engrafted GFP-positive cells were dis-
tributed in the muscularis, mucosa and villi of the recipi-
ent intestine (Figure 6B). Some transplanted cells were
located in close proximity to the submucosal and my-
enteric plexuses of the host intestine (Figure 6C). A subset
of the GFP-labeled engrafted cells were also positive for
protein gene product 9.5, indicating differentiation of
these NSCs into mature neurons post transplantation
(Figure 6C). The engrafted NSCs did not stain positive for
the glial cell marker GFAP (data not shown), indicating
that the engrafted NSCs did not differentiate into glial
cells after transplantation. In addition, western blot
analysis of LMMP strips revealed decreased expression
of the pan-neuronal marker peripherin, the glial cell
marker GFAP, and nNOS in rat pups with NEC. How-
ever, NSC implantation led to a significant increase in
the expression of peripherin and nNOS 4 days after
transplantation (Figure 6D, E).
Neural stem cell transplantation protects the intestines,
promotes motility, and increases survival in experimental
necrotizing enterocolitis
Intestine from animals exposed to experimental NEC that
received NSC transplantation had significantly longer vil-
lous length compared with intestine from nontransplanted
animals (Figure 7A, B). Although the villous structure was
well preserved, vacuolization in enterocytes was found innecrotizing enterocolitis. (A) Representative hematoxylin-and-eosin-
pup exposed to experimental necrotizing enterocolitis (NEC) for 3 days
protein (GFAP), and neuronal nitric oxide synthase (nNOS) immunohis-
Figure 6 Enteric neural stem cell transplantation protects the intestines in experimental necrotizing enterocolitis. (A) Outline of the
experimental protocol used. Rat pups were delivered by Cesarean section and then exposed to repeated episodes of hypoxia, hyperthermia, and
hypertonic formula feeding for 3 days to induce experimental necrotizing enterocolitis (NEC). Pups then received intraperitoneal (IP)
administration of green fluorescence protein (GFP)-labeled neural stem cells (NSCs) or carrier medium only, after which they were maintained on
normal feeds with discontinuation of stress for an additional 4 days. (B) Representative images of intestinal sections from breast-fed rat pups,
from pups exposed to NEC, and from pups exposed to NEC but treated with NSC transplantation. GFP-labeled transplanted cells were visualized
in intestinal tissue sections by anti-GFP immunohistochemistry, and were further characterized by protein gene product 9.5 (PGP9.5) staining to
identify mature neurons. (C) High magnification of the merged image inset (white box) demonstrating that transplanted NSCs have engrafted
into the submucosal plexus (S. Plexus; arrows) and myenteric plexus (M. Plexus; arrowheads) of the intestine and have differentiated into
PGP9.5-positive mature neurons (merged yellow staining). (D) Western blot analysis of intestinal longitudinal muscle–myenteric plexus strips
showing protein expression of peripherin and neuronal nitric oxide synthase (nNOS). (E) Quantification of the intensity of immunoreactive bands:
the band intensity ratios of peripherin to β-actin, nNOS to β-actin, and glial fibrillary acid protein (GFAP) to β-actin were calculated and are
expressed as mean ± standard error of the mean, n = 4. *P <0.05; +P <0.01. Scale bars: (B) 100 μm; (C) 25 μm.
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the response of the enterocytes to exposure to hypoxia,
hyperthermia and administration of hypertonic feeds in
the NEC animal model. In addition, host immune rejec-
tion of the transplanted mouse NSCs could also lead tocytoplasmic vacuolization. Rat pups exposed to experi-
mental NEC had significantly decreased intestinal motility
after 4 days of recovery from NEC, whereas animals ex-
posed to NEC that received NSC transplantation had
significantly improved intestinal transit (71.3 ± 8.8% vs.
Figure 7 Enteric neural stem cell transplantation restores intestinal integrity, promotes intestinal motility, and improves survival after
experimental necrotizing enterocolitis. (A) Representative hematoxylin-and-eosin-stained histologic images of ileal sections from pups exposed
to breast feeding, experimental necrotizing enterocolitis (NEC), or experimental NEC treated with neural stem cell (NSC) transplantation. (B) Quan-
tification of villous length, measured as the distance from the crypt neck to the villous tip using Image J software (NIH, Bethesda, MD, USA). Data
presented as mean ± standard error of the mean (SEM), n = 6 animals in each group. *P <0.05; +P <0.01. (C) Representative images of rat pups
with methylene blue dye migration determined at day 7 after birth. White arrowheads indicate the most distal aspect of dye migration. St, stom-
ach; Ce, cecum. (D) Effect of neurotransplantation on intestinal transit of methylene blue. Dye migration was measured as the ratio of migration
distance/total intestinal length. Results expressed as mean ± SEM. Six to eight pups were used in each group. +P <0.01. (E) Survival rate of rat pups
after experimental NEC with or without NSC transplantation. n = 28, *P <0.05 for NSC transplantation group versus control medium group.
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NSC transplantation also significantly improved the
survival rate of animals subjected to experimental NEC
at 2, 3 and 4 days post transplantation (Figure 7E).
Discussion
Although the pathophysiology of NEC remains elusive,
immaturity of the intestinal tract has been implicated in
its development. The ENS is comprised of neurons and
supportive glial cells present in two major plexuses, the
myenteric plexus and the submucosal plexus, that con-
trol the physiologic functions of the gastrointestinal tract
[24]. A significant reduction in glial cells, associated with
a gradual deterioration of intestinal neurons, has been
identified in intestine resected for NEC [9,10]. In this
study, we have confirmed that NEC is associated with
neuronal and glial cell loss in the ENS. Importantly, the
numbers of enteric glial cells remained low in the intes-
tines from NEC patients even months after the acute
episode when the patients underwent stoma closure.
This suggests that intrinsic immaturity of the ENS,
or dysfunctional glial cells, may predispose premature
babies to NEC. The decrease in glial cells with NEC is
surprising given that ischemia or inflammation is a
powerful stimulus to glial cell proliferation or GFAPexpression, such as that which occurs with 2,4,6-trinitro-
benzene sulfonic acid-mediated inflammation of the
gastrointestinal tract [25], or in inflammatory diseases of
the gut such as ulcerative colitis [26]. Acute failure of
enteric glia could be an upstream event in the cascade
that precipitates the ischemic insult resulting in NEC.
A previous study showed that ablation of enteric glial
cells leads to fulminant and fatal intestinal inflammation,
which is very consistent with the histopathologic changes
seen in NEC [27]. While the mechanisms of neuronal
cell loss have not been studied in patients with NEC,
deprivation of neurotropic factors such as nerve growth
factor and glial-derived neurotrophic factor that are
normally provided by supportive glial cells may lead to
activation of apoptotic pathways. In the current study,
we demonstrated the presence of neuronal apoptosis
via activation of a caspase-3-dependent pathway. Strong
activated caspase-3 immunoreactivity was evident in
the myenteric and submucosal ganglia of the intestines
from NEC patients, with similar findings observed in
the ENS of animals subjected to experimental NEC. Re-
cent reports showed that GFAP-positive glia exert an
anti-apoptotic effect on intestinal epithelial cells and pre-
serve mucosal integrity by limiting epithelial damage and
promoting epithelial reconstitution during inflammation
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ture newborns, or lack of growth factors in formula feed-
ing, may contribute to the impairment of the epithelial
lining that leads to acute NEC.
Loss of specific neuronal subpopulations in the my-
enteric plexus has been reported during aging or disease,
or in animals with specific genetic defects, indicating
that neuronal subpopulations respond differently to in-
jury or growth factor deprivation [30-32]. We found
that patients with NEC have loosely packed myenteric
neurons, with small neurons remaining in the my-
enteric ganglia. It is possible that the larger myenteric
neurons were affected more dramatically, leading to
loss of these cells. Preferential loss of large ganglion
cells has also been reported by others [33,34], and large
motor neurons appeared to be more vulnerable to some
diseases or to be the first group to die during injury
[35,36]. Further study of the vulnerability of some spe-
cific neuronal subpopulations such as motor neurons
during NEC is required.
Among the subpopulations of neurons in the ENS,
nNOS-immunoreactive neurons are more abundant in
the myenteric plexus compared with the submucosal
plexus [20]. The constitutive expression of nNOS in the
gastrointestinal tract maintains the regulated production
of low levels of nitric oxide, which acts as a predomin-
ant inhibitory neurotransmitter. Nitric oxide, mainly
produced by enteric neurons and glial cells, causes re-
laxation of the intestinal smooth muscle in response to
nerve stimulation, which is important in gut motility
[37,38]. Nitric oxide signaling also regulates proliferation
and differentiation of neural precursor cells [39,40].
Although changes in nNOS with NEC have not been re-
ported, there is one report of decreased nNOS expression
in a rat model of lipopolysaccharide-induced intestinal
injury [41]. This is the first report to demonstrate that
clinical NEC is associated with significantly decreased ex-
pression of nNOS not only during the acute event, but
also months later. This decreased nNOS expression may
explain the long-term intestinal dysmotility seen in NEC
patients even after recovery from the acute event.
Current therapy for intestinal dysmotility is limited
mainly to palliation, and new treatments for this debilitat-
ing condition are clearly needed. A promising intervention
involves NSC transplantation. In efforts to develop stem
cells therapies for ENS disorders, several sources of NSCs
have been explored, including NSCs derived from toti-
potent embryonic stem cells, NSCs derived from the fetal
or adult central nervous system, NSCs derived from fetal or
adult intestine (enteric NSCs) and NSCs derived from non-
neuronal sources (mesenchymal stem cells, amniotic fluid-
derived stem cells) [42]. Enteric NSCs are isolated from the
intestine and form neurospheres that contain nestin-
positive NSCs capable of differentiating into neurons andglial cells when growth factors are withdrawn. Enteric
NSCs, by virtue of their intestinal origin, may be more suit-
able for therapeutic purposes since they may respond better
to intestinal-specific environmental cues upon transplant-
ation [42,43]. Several reports have already described func-
tional success of NSC transplantation for other diseases.
NSCs transplanted either by direct injection into the intes-
tinal wall or by i.p. administration led to the engraftment of
NSCs in the myenteric plexus, and the generation of neu-
rons in ganglionated small bowel and colon as well as agan-
glionic rectum [17]. Whereas direct intramural injection
resulted in clumps of cells, i.p. injection resulted in diffuse
engraftment throughout the gastrointestinal tract, repre-
senting a clinically viable route of administration, especially
if generalized areas of intestine need to be treated. We have
previously shown that i.p. administration of mesenchymal
stem cells is an effective delivery route of stem cells in ex-
perimental NEC, as it avoids passive entrapment of trans-
planted cells in the pulmonary capillary bed [16]. Based on
this, we used i.p. administration of NSCs in the current
study, and documented engrafted cells in the submucosal
and myenteric plexuses after transplantation. However,
i.p. injection of NSCs to breast-fed normal rat pups did not
result in engraftment of cells in the intestines (data not
shown), suggesting that the cytokines and chemokines se-
creted by the injured intestine in experimental NEC are
crucial in directing the mobilization, migration and homing
of stem cells to the injured ENS. Others have shown that
enteric NSCs isolated from embryonic intestine were com-
mitted to differentiate into neurons and glial cells [44]. Al-
though the precise local factors responsible for transplanted
NSC differentiation have not been identified, our results
suggest that the gut environment provides a predominantly
neurogenic drive for NSCs, with differentiated neurons but
not glial cells identified in the recipient intestine post
transplantation.
For future clinical neurotransplantation in human pa-
tients with NEC, collection of NSCs from fetal gut or from
postnatal myenteric plexuses is not clinically practical. In
a parallel study, we found that NSCs can be selectively in-
duced from amniotic fluid-derived multipotent stem cells.
Based on this, amniotic fluid could be collected at the
time of delivery, amniotic fluid-derived stem cells cul-
tured, and the cells induced into NSCs in the laboratory.
The abundant availability of amniotic fluid meets the re-
quirement for large numbers of stem cells for transplant-
ation. NSC transplantation may represent a novel future
potential therapeutic strategy for those premature new-
borns at highest risk of developing NEC, or those with
early stages of the disease.
Conclusion
In summary, our results confirm significant ENS damage
during clinical and experimental NEC. Engraftment of
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pression in the ENS, to preserved intestinal integrity
with elongation of villous length, to significantly im-
proved intestinal motility, and to significantly increased
survival after experimental NEC. These results support a
future potential clinical role for enteric NSC transplant-
ation in patients with NEC.
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